CN109562114A - 用于治疗实体瘤的给药方案 - Google Patents

用于治疗实体瘤的给药方案 Download PDF

Info

Publication number
CN109562114A
CN109562114A CN201780052146.2A CN201780052146A CN109562114A CN 109562114 A CN109562114 A CN 109562114A CN 201780052146 A CN201780052146 A CN 201780052146A CN 109562114 A CN109562114 A CN 109562114A
Authority
CN
China
Prior art keywords
oxo
cancer
doses
week
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780052146.2A
Other languages
English (en)
Chinese (zh)
Inventor
K.A.本哈吉
E.S.M.袁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202310314953.4A priority Critical patent/CN116473978A/zh
Publication of CN109562114A publication Critical patent/CN109562114A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780052146.2A 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案 Pending CN109562114A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310314953.4A CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
US62/381911 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310314953.4A Division CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Publications (1)

Publication Number Publication Date
CN109562114A true CN109562114A (zh) 2019-04-02

Family

ID=59772787

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780052146.2A Pending CN109562114A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案
CN202310314953.4A Pending CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310314953.4A Pending CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Country Status (14)

Country Link
US (1) US20190209581A1 (https=)
EP (1) EP3506905B1 (https=)
JP (2) JP2019526632A (https=)
KR (1) KR102512899B1 (https=)
CN (2) CN109562114A (https=)
AU (1) AU2017321011B2 (https=)
BR (1) BR112019002461A2 (https=)
CA (1) CA3035616A1 (https=)
ES (1) ES2977556T3 (https=)
IL (2) IL264924B2 (https=)
MA (1) MA46086A (https=)
MX (1) MX387397B (https=)
SG (2) SG11201901325UA (https=)
WO (1) WO2018044662A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
MA45025A (fr) 2016-05-20 2019-03-27 Lilly Co Eli Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2013016081A1 (en) * 2011-07-27 2013-01-31 Eli Lilly And Company Notch pathway signaling inhibitor compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
EP2214679B1 (en) * 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
CA2952315A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2013016081A1 (en) * 2011-07-27 2013-01-31 Eli Lilly And Company Notch pathway signaling inhibitor compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE MASSARD 等: "Fisrt-in-human study of LY3039478,a Notch signaling inhibitor in advanced or metastatic cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *
EUNICE YUEN 等: "Abstract CT048:Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor,LY3039478,in the first-in-man study", 《CANCER RESEARCH》 *

Also Published As

Publication number Publication date
AU2017321011A1 (en) 2019-02-21
SG11201901325UA (en) 2019-03-28
BR112019002461A2 (pt) 2019-05-14
IL264924B1 (en) 2023-09-01
EP3506905A1 (en) 2019-07-10
EP3506905B1 (en) 2024-03-20
CA3035616A1 (en) 2018-03-08
IL264924B2 (en) 2024-01-01
KR20190042591A (ko) 2019-04-24
MA46086A (fr) 2019-07-10
JP2019526632A (ja) 2019-09-19
WO2018044662A1 (en) 2018-03-08
JP2023052108A (ja) 2023-04-11
ES2977556T3 (es) 2024-08-26
IL264924A (https=) 2019-04-30
KR102512899B1 (ko) 2023-03-23
US20190209581A1 (en) 2019-07-11
MX387397B (es) 2025-03-18
SG10202107832UA (en) 2021-09-29
AU2017321011B2 (en) 2023-08-03
IL305136A (en) 2023-10-01
CN116473978A (zh) 2023-07-25
MX2019002066A (es) 2019-06-03

Similar Documents

Publication Publication Date Title
CN109562114A (zh) 用于治疗实体瘤的给药方案
Ajani et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology
Yap et al. Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2-and non–BRCA1/2-mutant cancers
Martínez-Ricarte et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid
Mileshkin et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non–small cell lung cancer treated with erlotinib
Hall et al. A phase I study of pegylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma
Omura et al. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism
Dolly et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors
Desai et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
Bensch et al. 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors
Cullinane et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development
Mackay et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer
Bausch et al. Plectin-1 as a novel biomarker for pancreatic cancer
Hillestad et al. MRI distinguishes tumor hypoxia levels of different prognostic and biological significance in cervical cancer
Kim et al. Impact of emergent circulating tumor DNA RAS mutation in panitumumab-treated chemoresistant metastatic colorectal cancer
Wuest et al. Molecular imaging of GLUT1 and GLUT5 in breast cancer: a multitracer positron emission tomography imaging study in mice
Grellety et al. Enhancing abiraterone acetate efficacy in androgen receptor–positive triple-negative breast cancer: Chk1 as a potential target
Ligon et al. A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma
Coriat et al. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
Casey et al. Fumarate metabolic signature for the detection of reed syndrome in humans
He et al. Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
Zhao et al. CUB domain-containing protein 1 (CDCP1) is a target for radioligand therapy in castration-resistant prostate cancer, including PSMA null disease
US20130237546A1 (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
Rathkopf et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer
US20240197928A1 (en) Sodium-dependent glucose transporter 2 as a diagnostic and therapeutic target for pre-malignant lesions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination